candesartan has been researched along with Weight Reduction in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the change in weight over 6 months in 6933 patients in the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) programme, and its association with subsequent mortality (1435 deaths) over a median 32." | 9.13 | Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. ( Anker, SD; Dobson, J; Granger, CB; McMurray, JJ; Michelson, EL; Ostergren, J; Pfeffer, MA; Pocock, SJ; Solomon, SD; Swedberg, KB; Yusuf, S, 2008) |
| " The aim of this study was to investigate whether weight reduction after AT(1)-blockade is dependent on dose, blood pressure reduction and leptin signalling." | 7.77 | Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. ( Jöhren, O; Markert, A; Müller-Fielitz, H; Pahlke, F; Raasch, W; Wittmershaus, C, 2011) |
| "We investigated the change in weight over 6 months in 6933 patients in the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) programme, and its association with subsequent mortality (1435 deaths) over a median 32." | 5.13 | Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. ( Anker, SD; Dobson, J; Granger, CB; McMurray, JJ; Michelson, EL; Ostergren, J; Pfeffer, MA; Pocock, SJ; Solomon, SD; Swedberg, KB; Yusuf, S, 2008) |
| " The aim of this study was to investigate whether weight reduction after AT(1)-blockade is dependent on dose, blood pressure reduction and leptin signalling." | 3.77 | Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. ( Jöhren, O; Markert, A; Müller-Fielitz, H; Pahlke, F; Raasch, W; Wittmershaus, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pocock, SJ | 1 |
| McMurray, JJ | 1 |
| Dobson, J | 1 |
| Yusuf, S | 1 |
| Granger, CB | 1 |
| Michelson, EL | 1 |
| Ostergren, J | 1 |
| Pfeffer, MA | 1 |
| Solomon, SD | 1 |
| Anker, SD | 1 |
| Swedberg, KB | 1 |
| Müller-Fielitz, H | 1 |
| Markert, A | 1 |
| Wittmershaus, C | 1 |
| Pahlke, F | 1 |
| Jöhren, O | 1 |
| Raasch, W | 1 |
1 trial available for candesartan and Weight Reduction
| Article | Year |
|---|---|
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2008 |
1 other study available for candesartan and Weight Reduction
| Article | Year |
|---|---|
Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2011 |